International prescribing practices in obsessive-compulsive disorder (OCD).

Journal: Human psychopharmacology

Volume: 31

Issue: 4

Year of Publication: 2017

Affiliated Institutions:  Department of Psychiatry, The University of Sydney and Nepean Hospital, Sydney Medical School-Nepean, Discipline of Psychiatry, Sydney/Penrith, NSW, Australia. Department of Personality Psychology, Research Unit for Obsessive-Compulsive and Related Disorders, I'TOC, Faculty of Psychology, Universidad de Valencia, Spain. Dipartimento di Medicina Clinica e Sperimentale, Section of Psychiatry, Dipartmento di Farmacia, University of Pisa, Italy. Department of Psychiatry, Federal University of Health Sciences of Porto Alegre, Brazil. Department of Psychiatry and Legal Medicine, Federal University of Rio de Janeiro, Brazil. MRC Unit on Anxiety Disorders, Department of Psychiatry, University of Stellenbosch, Cape Town, South Africa. NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia. Department of Neuropsychiatry, Hyogo College of Medicine, Hyogo, Japan. Department and Institute of Psychiatry, University of São Paulo School of Medicine, Brazil. Department of Psychiatry National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India. Child and Adolescent Psychiatry Unit (UPIA) at the Department of Psychiatry, Federal University of São Paulo, Brazil.

Abstract summary 

To assess rates of psychotropic medication use in patients with obsessive-compulsive disorder (OCD) in seven different countries on five continents and to compare these with international treatment guidelines.Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their patients with OCD and on their incidence of psychotropic use. Consistency of summary statistics across countries was evaluated.The data came from Brazil (n = 955), Italy (n = 750), South Africa (n = 555), Japan (n = 382), Australia (n = 213), India (n = 202) and Spain (n = 82). The majority (77.9%; n = 2445) of the total sample of 3139 participants received a psychotropic medication. Consistent with international guidelines, selective serotonin reuptake inhibitors (SSRIs) were most commonly used (73.5%, n = 1796), but their use ranged from 59% in Australia to 96% in Japan. Clomipramine use varied from 5% in Japan and South Africa to 26% in India and Italy. Atypical antipsychotic use ranged from 12% in South Africa to 50% in Japan.Pharmacotherapy for OCD varied significantly across sites. Prospective studies are required to determine the cultural, pharmacoeconomic and pharmacogenomic factors that may play a role in the variation in prescribing practices internationally and whether these variations influence treatment outcomes. Copyright © 2016 John Wiley & Sons, Ltd.

Authors & Co-authors:  Brakoulias Vlasios V Starcevic Vladan V Belloch Amparo A Dell'Osso Liliana L Ferrão Ygor A YA Fontenelle Leonardo F LF Lochner Christine C Marazziti Donatella D Martin Andrew A Matsunaga Hisato H Miguel Euripedes C EC Reddy Y C Janardhan YC do Rosário Maria C MC Shavitt Roseli G RG Sundar Arumugham Shyam AS Stein Dan Joseph DJ Viswasam Kirupamani K

Study Outcome 

Source Link: Visit source

Statistics
Citations : 
Authors :  17
Identifiers
Doi : 10.1002/hup.2541
SSN : 1099-1077
Study Population
Male,Female
Mesh Terms
Adult
Other Terms
antipsychotics;benzodiazepines;cross-cultural study;medication;obsessive-compulsive disorder;pharmacotherapy;selective serotonin re-uptake inhibitors
Study Design
Cross Sectional Study
Study Approach
Country of Study
South Africa
Publication Country
England